$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

$slrx Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000161521917000080 Filed on November 06, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$282.8K	$413.6K	$599.1K
YoY Change	-5.38%	-30.96%
Cost Of Revenue	$133.3K	$148.8K	$221.1K
YoY Change	-0.27%	-32.72%
Gross Profit	$149.5K	$264.8K	$378.0K
YoY Change	-9.51%	-29.93%
Gross Profit Margin	52.85%	64.03%	63.09%
Selling, General & Admin	$3.980M	$4.930M	$5.450M
YoY Change	1.53%	-9.54%	15.47%
% of Gross Profit	2662.47%	1861.47%	1441.86%
Research & Development	$4.259M	$4.739M	$5.665M
YoY Change	0.67%	-16.34%	64.44%
% of Gross Profit	2849.35%	1789.48%	1498.84%
Depreciation & Amortization	$70.00K	$80.00K	$80.00K
YoY Change	-36.36%	0.0%	700.0%
% of Gross Profit	46.83%	30.21%	21.16%
Operating Expenses	$8.376M	$9.823M	$11.33M
YoY Change	1.12%	-13.33%	38.77%
Operating Profit	-$8.093M	-$9.409M	-$10.74M
YoY Change	1.36%	-12.35%	31.44%
Interest Expense	$60.00K	$80.00K	$100.0K
YoY Change	-25.0%	-20.0%	900.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$8.030M	-$9.330M	-$10.74M
YoY Change	0.57%	-13.09%	31.44%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.029M	-$9.332M	-$10.64M
YoY Change	1.63%	-12.27%	30.48%
Net Earnings / Revenue	-2838.66%	-2256.31%	-1775.66%
Basic Earnings Per Share
Diluted Earnings Per Share	-$11.31M	-$13.33M	-$16.37M
COMMON SHARES
Basic Shares Outstanding	17.97M shares	17.97M shares	17.97M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.30M	$38.90M	$67.30M
YoY Change	-45.5%	-42.2%	-32.16%
Cash & Equivalents	$19.19M	$20.41M	$27.80M
Short-Term Investments	$14.10M	$18.80M	$39.50M
Other Short-Term Assets	$800.0K	$1.100M	$1.600M
YoY Change	-11.11%	-31.25%	45.45%
Inventory	$431.9K	$534.0K	$230.8K
Prepaid Expenses
Receivables	$10.39K	$35.13K	$21.79K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$34.54M	$40.55M	$69.14M
YoY Change	-44.71%	-41.35%	-31.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$331.0K	$401.0K	$619.4K
YoY Change	-40.49%	-35.26%	142.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change
Other Assets	$0.00	$0.00	$64.80K
YoY Change	-100.0%	-100.0%	-23.94%
Total Long-Term Assets	$457.6K	$654.2K	$810.8K
YoY Change	-38.8%	-19.31%	56.57%
TOTAL ASSETS
Total Short-Term Assets	$34.54M	$40.55M	$69.14M
Total Long-Term Assets	$457.6K	$654.2K	$810.8K
Total Assets	$34.99M	$41.21M	$69.95M
YoY Change	-44.64%	-41.09%	-30.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.004M	$919.0K	$1.257M
YoY Change	68.13%	-26.88%	81.45%
Accrued Expenses	$3.700M	$3.900M	$2.500M
YoY Change	42.31%	56.0%	66.67%
Deferred Revenue	$72.19K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.848M	$4.973M	$3.913M
YoY Change	50.36%	27.08%	68.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$100.0K	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$0.00	$100.0K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.848M	$4.973M	$3.913M
Total Long-Term Liabilities	$0.00	$100.0K	$0.00
Total Liabilities	$5.887M	$5.027M	$3.924M
YoY Change	51.04%	28.11%	42.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$111.1M	-$103.1M	-$68.75M
YoY Change	44.93%	49.9%	134.95%
Common Stock	$1.780K	$1.754K	$1.652K
YoY Change	6.08%	6.17%	6.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.900M	$36.18M	$66.03M
YoY Change
Total Liabilities & Shareholders Equity	$34.99M	$41.21M	$69.95M
YoY Change	-44.64%	-41.09%	-30.58%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$8.029M	-$9.332M	-$10.64M
YoY Change	1.63%	-12.27%	30.48%
Depreciation, Depletion And Amortization	$70.00K	$80.00K	$80.00K
YoY Change	-36.36%	0.0%	700.0%
Cash From Operating Activities	-$5.750M	-$8.050M	-$7.250M
YoY Change	-8.73%	11.03%	8.21%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$50.00K	-$220.0K
YoY Change	-80.0%	-77.27%	57.14%
Acquisitions
YoY Change
Other Investing Activities	$4.670M	-$10.75M	-$3.660M
YoY Change	396.81%	193.72%	-63.4%
Cash From Investing Activities	$4.660M	-$10.79M	-$3.880M
YoY Change	423.6%	178.09%	-61.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	10.00K
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-5.750M	-8.050M	-7.250M
Cash From Investing Activities	4.660M	-10.79M	-3.880M
Cash From Financing Activities	0.000	0.000	10.00K
Net Change In Cash	-1.090M	-18.84M	-11.12M
YoY Change	-79.85%	69.42%	-34.01%
FREE CASH FLOW
Cash From Operating Activities	-$5.750M	-$8.050M	-$7.250M
Capital Expenditures	-$10.00K	-$50.00K	-$220.0K
Free Cash Flow	-$5.740M	-$8.000M	-$7.030M
YoY Change	-8.16%	13.8%	7.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.96
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001615219
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17971816	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Flex Pharma, Inc.
CY2016Q4	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2587573	USD
CY2017Q3	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3897184	USD
CY2016Q4	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	938665	USD
CY2017Q3	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	2784448	USD
	flks	Inventory Purchasesin Accounts Payableand Accrued Expense InventoryPurchasesinAccountsPayableandAccruedExpense	121077	USD
	flks	Inventory Purchasesin Accounts Payableand Accrued Expense InventoryPurchasesinAccountsPayableandAccruedExpense	0	USD
	flks	Property And Equipment Purchases In Accrued Expense PropertyAndEquipmentPurchasesInAccruedExpense	106680	USD
	flks	Property And Equipment Purchases In Accrued Expense PropertyAndEquipmentPurchasesInAccruedExpense	7100	USD
	flks	Revenue Recognition Refund Period RevenueRecognitionRefundPeriod	P30D
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1192183	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	919030	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12181	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35134	USD
CY2016Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	42024	USD
CY2017Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	135045	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	153219	USD
CY2017Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	187173	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1614	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1311	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	135962935	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	139231785	USD
CY2016Q3	us-gaap	Advertising Expense AdvertisingExpense	1154000	USD
	us-gaap	Advertising Expense AdvertisingExpense	2580000	USD
CY2016Q4	us-gaap	Assets Assets	63214979	USD
CY2017Q3	us-gaap	Assets Assets	41208009	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	62467269	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	40553828	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1860588	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5367070	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1004781	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3266879	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3772490	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3132361	shares
CY2017Q3	us-gaap	Advertising Expense AdvertisingExpense	1158000	USD
	us-gaap	Advertising Expense AdvertisingExpense	3073000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	38658933	USD
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	18776390	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2912	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	298	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4526	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1609	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	38660547	USD
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	18777701	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	16519620	USD
CY2017Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	9483010	USD
CY2016Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	6	security
CY2017Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	5	security
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8472	USD
CY2015Q4	us-gaap	Cash Cash	66686695	USD
CY2016Q3	us-gaap	Cash Cash	27829591	USD
CY2016Q4	us-gaap	Cash Cash	22416040	USD
CY2017Q3	us-gaap	Cash Cash	20152129	USD
CY2017Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	38928519	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-38857104	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-2263911	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17970590	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17971816	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16773798	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17541377	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1678	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	1754	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10662312	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31553762	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9327808	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26404828	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	221090	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	529041	USD
CY2017Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	148756	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	373187	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	21095	USD
CY2017Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	58821	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8398	USD
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	53919	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	88344	USD
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	97571	USD
	us-gaap	Depreciation Depreciation	165373	USD
	us-gaap	Depreciation Depreciation	250563	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.54
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1453665	USD
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	790518	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2017Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	5801434	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5447847	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15937326	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4934937	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14520596	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	321460	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-274525	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21787	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22953	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	647455	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1309611	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-3056	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	83247	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	81399	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	9227	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	109701	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	79864	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	64800	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-64800	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-15442	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	645696	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	130196	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-240	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	126595	USD
CY2016Q3	us-gaap	Interest Income Operating InterestIncomeOperating	97726	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	308877	USD
CY2017Q3	us-gaap	Interest Income Operating InterestIncomeOperating	77339	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	227535	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	454132	USD
CY2017Q3	us-gaap	Inventory Net InventoryNet	533996	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	19888	USD
CY2017Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	29409	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	434244	USD
CY2017Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	504587	USD
CY2016Q3	us-gaap	Inventory Write Down InventoryWriteDown	32734	USD
	us-gaap	Inventory Write Down InventoryWriteDown	258684	USD
CY2017Q3	us-gaap	Inventory Write Down InventoryWriteDown	14701	USD
CY2016Q4	us-gaap	Liabilities Liabilities	3897593	USD
	us-gaap	Inventory Write Down InventoryWriteDown	34235	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-117236	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	38551	USD
CY2017Q3	us-gaap	Liabilities Liabilities	5026525	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63214979	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41208009	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3889195	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4972606	USD
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	38658933	USD
CY2017Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	18776390	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22096	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2047	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13125863	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19827530	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25753337	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22093488	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-10637494	USD
	us-gaap	Net Income Loss NetIncomeLoss	-31593088	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-9332113	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26405131	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10637494	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-31593088	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9332113	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26405131	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	11334294	USD
	us-gaap	Operating Expenses OperatingExpenses	32613724	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	9823053	USD
	us-gaap	Operating Expenses OperatingExpenses	27624337	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10735220	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-31901965	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9409452	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26632666	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	64800	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2016Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-24818	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	39326	USD
CY2017Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	4305	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	303	USD
CY2016Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	12940	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	12940	USD
CY2017Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	6360	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	13450	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	28086686	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	23364721	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	508987	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	98100	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	925983	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1056179	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	15469810	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	43286118	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4233	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	22096	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2047	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	556315	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	400991	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5665357	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16147357	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4739360	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12730554	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	126595	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	253190	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76645613	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103050744	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	586134	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	698819	USD
CY2017Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	407241	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	978221	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	599074	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	711759	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	413601	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	991671	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5367070	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3266879	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1359109	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.49
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	471602	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1018500	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1605684	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	731233	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2156250	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2701922	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.66
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.87
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	731233	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2701922	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.87
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.67
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.37
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.23
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	610027	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M9D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M6D
CY2016Q3	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	98000	USD
	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	126000	USD
CY2017Q3	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	64000	USD
	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	145000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1226	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	59317386	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	36181484	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16361617	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16104510	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17386249	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17131887	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company outsources the manufacture of HOTSHOT to a single co-packer that produces bottled finished goods. The Company also sources certain raw materials from sole suppliers. A disruption in the supply of materials or the production of finished goods could significantly impact the Company's revenues in the future as alternative sources of raw materials and co-packing may not be available at commercially reasonable rates or within a reasonably short period of time. </font></div></div>
	us-gaap	Revenue Recognition Revenue Reductions RevenueRecognitionRevenueReductions	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Discounts provided to customers are accounted for as a reduction of net product revenue. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates, which include, but are not limited to, estimates related to clinical study accruals, estimates related to inventory realizability, stock-based compensation expense and amounts of expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001615219-17-000080-index-headers.html	Edgar Link	pending
0001615219-17-000080-index.html	Edgar Link	pending
0001615219-17-000080.txt	Edgar Link	pending
0001615219-17-000080-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
flks-20170930.xml	Edgar Link	completed
flks-20170930.xsd	Edgar Link	pending
flks-20170930_cal.xml	Edgar Link	unprocessable
flks-20170930_def.xml	Edgar Link	unprocessable
flks-20170930_lab.xml	Edgar Link	unprocessable
flks-20170930_pre.xml	Edgar Link	unprocessable
flks201793010-q.htm	Edgar Link	pending
flks2017930ex-102.htm	Edgar Link	pending
flks2017930ex-311.htm	Edgar Link	pending
flks2017930ex-312.htm	Edgar Link	pending
flks2017930ex-321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

2017 Q4 Form 10-Q Financial Statement

#000161521917000080 Filed on November 06, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX Salarius Pharmaceuticals, Inc. Stock $slrx

2017 Q4 Form 10-Q Financial Statement

#000161521917000080 Filed on November 06, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx